Since overexpressed antiapoptotic Bcl-xL protein in PDAC facilitated cancer cells to escape the apoptotic process, Bcl-xL inhibitors have been a strong candidate for a new treatment option for PDAC [37]. The gene discussed is BCL2L1; the disease is cancer.